UCT has announced that has filed a patent application with the United States Patent and Trademark Office for its innovative CA-62 Biomarker Cancer Test kit. The filing of the US Patent is the latest of a number of international patents, filed to protect the intellectual property rights of this new cancer test around the world. US Patent application number #202090834 was filed on December 7th beginning the patent review process for this important market.
Also of note, UCT’s Russian Patent application (#2018121107/04 (033263)) was approved on October 19, 2020 by the Russian Patent Office.
This follows other patent applications including the International Patent filed on May 28, 2019 (“SET OF REAGENTS FOR DETECTING A MARKER OF EPITHELIAL CARCINOMAS”. Application #PCT/RU2019/050069), and the Eurasian Patent on April 24, 2020 (Eurasian Patent Organization – Application #202090834).
“With our vision to commercialize our cancer test kit in markets around the globe, this patent strategy is a critical step in that plan”, UCT co-founder and CEO, Viatcheslav Kondratiev commented, “It allows us to protect our innovation while rolling out the tests to save the most lives through detecting cancer early.”
Contact
Viatcheslav Kondratiev, CEO
Universal Cancer Technologies (UCT)
800 Petrolia Road, Unit 3
Toronto, ON M3J 3K4 Canada
Phone: 416-661-7890
Email: [email protected]
About UCT
UCT is an emerging biotechnology company that has developed a sensitive cancer test that can reliably measure the amount of N-glycoprotein CA-62 biomarker in a routine blood draw. The test can detect the majority of epithelial cancer types at all stages of the disease (Stage I through Stage IV), even before a patient may become symptomatic. Because of its non-invasive approach and rapid turnaround time UCT’s CA-62 biomarker test is ideal for screening as well as for monitoring the success of ongoing cancer treatments and identifying relapses in remission patients.
-30-